Correlation Between Trane Technologies and CRISPR Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Trane Technologies and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Trane Technologies and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Trane Technologies plc and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Trane Technologies and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Trane Technologies with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Trane Technologies and CRISPR Therapeutics.

Diversification Opportunities for Trane Technologies and CRISPR Therapeutics

0.36
  Correlation Coefficient

Weak diversification

The 3 months correlation between Trane and CRISPR is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Trane Technologies plc and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Trane Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Trane Technologies plc are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Trane Technologies i.e., Trane Technologies and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Trane Technologies and CRISPR Therapeutics

Assuming the 90 days trading horizon Trane Technologies plc is expected to generate 1.07 times more return on investment than CRISPR Therapeutics. However, Trane Technologies is 1.07 times more volatile than CRISPR Therapeutics AG. It trades about 0.11 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about 0.03 per unit of risk. If you would invest  96,622  in Trane Technologies plc on October 10, 2024 and sell it today you would earn a total of  18,952  from holding Trane Technologies plc or generate 19.61% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy96.55%
ValuesDaily Returns

Trane Technologies plc  vs.  CRISPR Therapeutics AG

 Performance 
       Timeline  
Trane Technologies plc 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Trane Technologies plc are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Trane Technologies sustained solid returns over the last few months and may actually be approaching a breakup point.
CRISPR Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Trane Technologies and CRISPR Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Trane Technologies and CRISPR Therapeutics

The main advantage of trading using opposite Trane Technologies and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Trane Technologies position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.
The idea behind Trane Technologies plc and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Valuation
Check real value of public entities based on technical and fundamental data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance